Pregabalin Capsule
Product Images NDC 71335-1475

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-1475). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351475)

Label for Pregabalin Capsules, USP 100 mg by Bryant Ranch Prepack. The label includes the NDC 71335-1475-01, a red border around the strength, and states the package contains 30 capsules. It has the BRP Pharmaceuticals logo and instructions to keep out of reach of children and store at room temperature.*

FDA Label Image

Label (Lbl7133514752)

Label for Pregabalin 100 mg capsule by Bryant Ranch Prepack. The label indicates the capsule is red and compares it to Lyrica 100 mg capsule by Laurus Labs Limited. Storage instructions specify room temperature 20°-25°C (68°-77°F). Package count is 30 capsules. The NDC number 71335-1475-1 is shown along with a lot number and barcode.*

FDA Label Image

Pregabalinchemistrystructure (Pregabalin Chem Structure)

Chemical structure of Pregabalin depicted as a molecular diagram showing its arrangement of atoms and bonds.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula illustrating creatinine clearance (CLCr) calculation, showing the relationship between age in years, weight in kilograms, serum creatinine concentration in mg/dL, and an adjustment factor for female patients. This formula is commonly used to estimate kidney function.*

FDA Label Image

Pregabalinfig1 (Pregabalin Fig 01)

A line graph displaying percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 25 mg, 100 mg, and 200 mg taken three times a day compared to placebo. The x-axis shows percent improvement in pain, and the y-axis shows percent of patients improved.*

FDA Label Image

Pregabalinfig2 (Pregabalin Fig 02)

A graph showing the percent of patients improved on the vertical axis against percent improvement in pain from baseline on the horizontal axis. Two curves are compared: one for Pregabalin 100 mg three times a day and one for placebo, illustrating comparative effectiveness in pain improvement percentages.*

FDA Label Image

Pregabalinfig3 (Pregabalin Fig 03)

A line graph showing the percent of patients improved at various levels of percent improvement in pain from baseline. The graph compares Pregabalin at 75 mg, 150 mg, and 300 mg taken twice a day with placebo, illustrating the trend in patient improvement across these treatments.*

FDA Label Image

Pregabalinfig4 (Pregabalin Fig 04)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, illustrating patient response over varying degrees of pain improvement.*

FDA Label Image

Pregabalinfig5 (Pregabalin Fig 05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo. The graph shows three curves illustrating patient response across varying levels of pain improvement.*

FDA Label Image

Pregabalinfig6 (Pregabalin Fig 06)

Bar graph showing responder rates (%) from two clinical studies labeled Study E1 and Study E3. Study E1 compares placebo and Pregabalin doses (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day) with increasing responder rates. Study E3 compares placebo and Pregabalin at 600 mg/day with two different dosing intervals. Sample sizes for each group are shown below bars.*

FDA Label Image

Pregabalinfig7 (Pregabalin Fig 07)

A line graph depicting seizure reduction as median percent change from baseline on the y-axis against dose in mg/day on the x-axis. The graph shows four study groups labeled Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID, with corresponding data points and p-values indicating statistical significance. The graph compares seizure reduction across different doses and study groups, with placebo represented at zero dose.*

FDA Label Image

Pregabalinfig8 (Pregabalin Fig 08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin doses of 600 mg, 450 mg, 300 mg daily, and placebo. The vertical axis shows percent of patients improved from 0 to 100, and the horizontal axis shows percent pain improvement ranging from greater than 0 to 100.*

FDA Label Image

Pregabalinfig9 (Pregabalin Fig 09)

A survival plot chart comparing the estimated percentage of subjects without LTR over a period of 180 days between Pregabalin and Placebo groups. The Y-axis shows the percentage from 0% to 100%, and the X-axis represents days from 0 to 180. Pregabalin is indicated with a solid line, and Placebo with a dashed line.*

FDA Label Image

Pregabalinfig10 (Pregabalin Fig 10)

A line graph comparing percent of subjects improved over percent improvement from baseline to week 12 on BOCF scale for Pregabalin 100 mg and placebo. The y-axis shows percent of subjects improved from 0 to 100, and the x-axis shows percent improvement from baseline to week 12 from 0 to 100. Two lines depict Pregabalin (solid) and placebo (dashed) outcomes, showing higher improvement percentages for Pregabalin.*

FDA Label Image

Pregabalinfig11 (Pregabalin Fig 11)

A line chart comparing the percent of subjects improved over time between Pregabalin and placebo groups. The x-axis represents percent improvement from baseline to week 16 BOCF, ranging from 0 to 100%, and the y-axis shows the percent of subjects improved. The chart displays two lines: a solid line for Pregabalin and a dashed line for placebo, with Pregabalin showing consistently higher improvement percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.